FDA Approved: XALKORI — Supplemental Application (Pfizer Laboratories Div Pfizer Inc)

View source ↗

Summary

FDA approved a supplemental application for XALKORI (crizotinib) submitted by Pfizer Laboratories Div Pfizer Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Inflammatory Myofibroblastic Tumor
• Non-small Cell Lung Cancer

Drugs mentioned

• Xalkori (crizotinib)

Snippet

SUPPL AP for XALKORI (CRIZOTINIB)